BioSpace News Archive

Selux Diagnostics, Inc. announced the selection of two Selux abstracts for poster sessions at the upcoming ASM Microbe conference, the flagship scientific meeting hosted by the American Society for Microbiology, which resumed this year and is scheduled to take place on June 9-13 in Washington, DC.

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), announces the approval of its Investigational New Drug (IND) application by the United States Food and Drug Administration (US FDA) to evaluate its SAR-Bombesin product as an imaging agent in prostate cancer patients that are Prostate-Specific Membrane Antigen (PSMA)-negative.

Neurocrine Biosciences, Inc. was honored by the CARES Foundation for its ongoing research and development of novel therapies for patients with classic congenital adrenal hyperplasia.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided additional data on patients dosed in Part A of its Phase 1/2 clinical trial of VX‑880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with T1D with impaired hypoglycemic awareness and severe hypoglycemia.

Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering, announced today a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to optimize CAR designs for cellular therapy.

Blue Water Vaccines Inc., a biopharmaceutical company developing transformational vaccines to address significant global health challenges, announced that Joseph Hernandez, Chairman and Chief Executive Officer of BWV, will present at the JMP Securities Life Science Conference.

Cogent Biosciences, Inc.announced it will host an investor webcast on Friday, June 10, 2022 at 8:00am ET to discuss initial clinical data from its on-going Phase 2 APEX trial evaluating bezuclastinib in patients with Advanced Systemic Mastocytosis being presented at the European Hematology Association Congress.

Corcept Therapeutics Incorporated announced that, following consultation with the U.S. Food and Drug Administration, it will start a registrational Phase 3 trial of relacorilant plus nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will be presenting at the Goldman Sachs 43rd Annual Global Healthcare Conference.

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted both orphan drug and rare pediatric disease designations for inclacumab and GBT021601 (GBT601) for the treatment of sickle cell disease (SCD).